You are here

Exhaled Breath Biomarker May Detect Lung Cancer

Researchers develop breath-based clinical test (October 28)

Researchers at the Cleveland Clinic have discovered that lung cancer may be detected in patients by analyzing their exhaled breath. Moreover, preliminary studies suggest that an accurate exhaled breath biomarker could be developed for use as a clinical test. The new findings were presented at the 2013 American College of Chest Physicians (ACCP) annual meeting (CHEST 2013) in Chicago.

“We believe that cancer cells release a unique chemical signature related to the tumor-growing process,” said lead investigator Peter J. Mazzone, MD, FCCP. “We are currently developing a breath-based test based on the results of our research.”

Mazzone and his colleagues studied 82 subjects with biopsy-confirmed lung cancer who had not received treatment along with a control group of 155 people who were either at risk for lung cancer or had benign lung nodules.

The subjects were asked to breathe normally while their breath was exposed to a high-dimensional chemical sensor called a colorimetric sensor array. The colors on the array change when exposed to various chemicals. If the chemicals in the breath contained markers for lung cancer, the array would show that in a pattern of color changes.

The colorimetric sensor array continually monitored the chemicals exhaled from the subjects’ breath, resulting in sensor changes that accurately distinguished the breath of subjects with lung cancer from the control subjects.

Source: Medical Xpress; October 28, 2013.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs